Skip to main content

Table 2 Medication Use and Persistence by the 420 Patients Enrolled in the Stroke Outcome Study from 2001–2002 at the Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

From: Medication Persistence Rates and Factors Associated with Persistence in Patients Following Stroke: A Cohort Study

Drug category Users at discharge, n (%) Users at 6 months, n (%) Persistencea at 6 months (%) Users at 12 months, n (%)b Persistencec at 12 months (%)b
Antihyperglycemic 104 (24.8) 104 (24.8) 101/104 (97.1) 103 (25.6) 98/101 (97.0)
   Insulin 25 (6.0) 26 (6.2)   32 (8.0)  
   Oral agents 87 (20.7) 86 (20.5)   82 (20.4)  
Antihypertensive 384 (91.4) 374 (89.0) 363/384 (94.5) 355 (88.3) 348/367 (94.8)
   Diuretic 137 (32.6) 140 (33.3)   151 (37.6)  
   β-Blocker 182 (43.3) 176 (41.9)   166 (41.3)  
   CCB 96 (22.9) 102 (24.3)   96 (23.9)  
   ACE-I 317 (75.5) 291 (69.3)   272 (67.7)  
   ARB 21 (5.0) 34 (8.1)   40 (10.0)  
   Other 7 (1.7) 9 (2.1)   10 (2.5)  
Antithrombotic 405 (96.4) 392 (93.3) 385/405 (95.1) 379 (94.3) 372/387 (96.1)
   Antiplateletd 341 (81.7) 333 (79.3) 322/341 (94.4) 322 (80.1) 310/325 (95.4)
   Anticoagulantd 72 (17.1) 71 (16.9) 60/72 (83.3) 69 (17.2) 57/69 (82.6)
Antilipidemic 307 (73.1) 304 (72.4) 285/307 (92.8) 300 (74.6) 276/302 (91.4)
   Statin 306 (72.9) 295 (70.2)   293 (72.9)  
   Other 1 (0.2) 10 (2.4)   9 (2.2)  
Combination use      
   Antihypertensive and antithrombotic 373 (88.8) 360 (85.7)   342 (85.1)  
   Antihypertensive, antithrombotic and antilipidemic 286 (68.1) 284 (67.6)   274 (68.2)  
  1. ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker, CCB = calcium channel blocker
  2. aThe percentage of patients persistent at six months is the number of patients still receiving a drug from the drug category at six months divided by the total number who were prescribed a drug from the drug category at discharge
  3. bAt 12 months, 17 patients had died and 1 patient had a missing medication list leaving a total of 402 eligible for analysis
  4. cThe percentage of patients persistent at 12 months is the number of patients still receiving a drug from the drug category at 12 months divided by the total number who were prescribed a drug from the drug category at discharge and who completed the 12 month visit with a medication list
  5. d8 patients were prescribed both an anticoagulant and an antiplatelet at discharge